PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 52 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $16,000 | -70.9% | 91,850 | 0.0% | 0.00% | – |
| Q2 2022 | $55,000 | -52.6% | 91,850 | +4.6% | 0.00% | – |
| Q1 2022 | $116,000 | -43.7% | 87,850 | +11.1% | 0.00% | – |
| Q4 2021 | $206,000 | -16.3% | 79,078 | 0.0% | 0.00% | – |
| Q3 2021 | $246,000 | -16.3% | 79,078 | 0.0% | 0.00% | – |
| Q2 2021 | $294,000 | -75.4% | 79,078 | -77.1% | 0.00% | – |
| Q1 2021 | $1,193,000 | +27.7% | 344,657 | +24.0% | 0.00% | – |
| Q4 2020 | $934,000 | -11.6% | 277,957 | -7.6% | 0.00% | – |
| Q3 2020 | $1,056,000 | -11.0% | 300,757 | +16.5% | 0.00% | – |
| Q2 2020 | $1,187,000 | +43.9% | 258,083 | +3.5% | 0.00% | – |
| Q1 2020 | $825,000 | -41.2% | 249,310 | +8.5% | 0.00% | – |
| Q4 2019 | $1,404,000 | +52.1% | 229,779 | +3.9% | 0.00% | – |
| Q3 2019 | $923,000 | -41.1% | 221,242 | +16.6% | 0.00% | – |
| Q2 2019 | $1,567,000 | – | 189,674 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |